Submission Details

Molecule(s):
COc1nnc2c(NC(=O)Cc3cccc(Cl)c3)c(O)ncn12

EDJ-MED-97c1bf5c-1

COc1nnc2c(NC(=O)Cc3cccc(Cl)c3)c(O)ncn12

3-aminopyridine-like Check Availability on Manifold View
COc1ncn2nnnc2c1NC(=O)Cc1cccc(Cl)c1

EDJ-MED-97c1bf5c-2

COc1ncn2nnnc2c1NC(=O)Cc1cccc(Cl)c1

3-aminopyridine-like Check Availability on Manifold View
COc1ncn2nnnc2c1NC(=O)C1CCOc2ccc(Cl)cc21

EDJ-MED-97c1bf5c-3

COc1ncn2nnnc2c1NC(=O)C1CCOc2ccc(Cl)cc21

3-aminopyridine-like Check Availability on Manifold View
COc1ncn2cnnc2c1NC(=O)C1CCOc2ccc(Cl)cc21

EDJ-MED-97c1bf5c-4

COc1ncn2cnnc2c1NC(=O)C1CCOc2ccc(Cl)cc21

3-aminopyridine-like Check Availability on Manifold View
COc1ncn2c(O)nnc2c1NC(=O)C1CCOc2ccc(Cl)cc21

EDJ-MED-97c1bf5c-5

COc1ncn2c(O)nnc2c1NC(=O)C1CCOc2ccc(Cl)cc21

3-aminopyridine-like Check Availability on Manifold View

Design Rationale:

Based on available bicyclic aminoheterocycles at Enamine - discussion with Oleg Michurin suggested that the heterocyclic Cl analogues are too reactive therefore replace the activated Cl with OMe as the methoxy isoquinoline is essentially equipotent with the isoquinoline.

Discussion: